Epitomics, the San Francisco-area biopharma with two major facilities in China, intends to IPO on the Taiwan Stock Exchange before the end of the year. Epitomics’ business model is based on the company’s proprietary RabMAb® monoclonal antibody technology,

In California, word came from Solazyme that they have priced their IPO at $18 and will rake in an industrial biotech record of $227M, should underwriters also sell 1.65 million additional shares in over-allotments over the next 30 days.

Rosetta Genomics, Ltd. (NASDAQ: ROSG) today announced the closing of an initial public offering (IPO) of its majority-owned subsidiary, Rosetta Green, in Israel which raised gross proceeds of 21,900,960 NIS ($6.06 million). Shares of Rosetta Green will trade on the Tel Aviv Stock Exchange (TASE) under the ticker symbol, "RSTG" beginning on February 23, 2011.

AcelRx Pharmaceuticals, which filed paperwork last November for an initial public offering on the Nasdaq exchange, set its IPO terms in an updated regulatory filing yesterday.

BG Medicine, the Waltham, MA-based diagnostics company, said it has received FDA clearance for its lead product in development, a new test to measure the progress of patients with chronic heart failure.

Japanese drugmaker Otsuka Holdings plans to sell about $2.8 billion worth of shares in December, marking the world's largest initial public offering in the pharmaceuticals sector.

An HIV company set up a year ago by GlaxoSmithKline Plc (GSK.L) and Pfizer Inc (PFE.N) could be spun off and floated in an initial public offering once its drug pipeline has matured a little further.

Endocyte, Inc., a biopharmaceutical company developing targeted small-molecule drug conjugates, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.